Why Repare Therapeutics Stock Is Skyrocketing Today
Copyright 1995-2022 The Motley Fool. All rights reserved.
finance
2022-06-02 16:30:28

After the market closed Wednesday, Repare Therapeutics (RPTX 39.80%) announced that it had entered into a licensing and collaboration deal with Roche (RHHBY 1.16%) for its experimental cancer drug, camonsertib, also known as RP-3500. In the wake of that news, Repare shares skyrocketed, and were up by 36.5% as of 11:58 a.m. ET on Thursday.  So what
Major deals with big partners almost always provide solid catalysts for biotech stocks. The spectacular gain for Repare Thursday seems to be warranted, especially in light of the details of its agreement with the Swiss healthcare giant.
